EXPRESSION OF CD-31/CD-34 IN PATIENTS WITH І-ІІ STAGES NON-SMALL CELL LUNG CANCER
DOI:
https://doi.org/10.14739/2310-1210.2013.6.20679Keywords:
non-small cell lung cancer, survival, CD31/CD34Abstract
Introduction. Individualization of patients with lung cancer treatment remains one of pressing questions of modern oncology. One of main markers are CD31/CD34 – that can help to assess microvessel density (MD) in the tumor. The aim of our work was to evaluate MD in the tumor in patients with early stages NSCLC, and assess correlation of this factor with clinico-morphologycal criterions and prognosis for patients.
Materials and methods. MD assessment was conducted in 241 patients with І-ІІ studies of NSCLC. All patients were treated in Zaporozhye regional clinical oncology center since June 2008 to December 2012. 202 of them were men (83,8%) and 39 - women (16,2%). Mean age of the patients that were included in the study was 60,9 year (95% ВІ, 59,9-61,9). After operation immunohistochemical analysis of tumors were performed. MD assessed with help of the CD31/CD34 markers. All statistic analysis conducted in program “Statistica 6.0”.
Results. Mean count of microvessels in tumors were 68,7±2,1 (95%, CI: 64,5-72,9%). For more convenient analysis of prognosis, all patients were divided in two groups. First group: patients with high MD in the tumor (≥63 microvessels), and another one – patients with low MD in the tumor (<63 microvessels).
No any correlation between age, sex, body mass index of patients, locations, “T”, “N” criteria, stage of disease and microvessel density in the tumor was founded. Also, no correlation between MD and histologyc type of tumor, necrosis in the tumor and infiltration of visceral pleura was presented.
Survival in patients with low MD in the tumor was better than survival in patients with high MD in the malignances. Means of survival of patients with low MD in the tumor was 52,7±2,8 month (95%, CI: 47,3-58,2). At the same time, survival in patients with high MD was 35,6±3,2 month (95%, CI, 29,4-41,8). Median of survival patients with low MD has not reached. Median of survival patients with high MD was 30,0±8,9 month. So, survival of patients with low MD was better than survival in patients with high MD in the tumor. Also, Log-rank confirmed this statement (р=0,00017).
Conclusion:
- CD31/CD34 expression analysis and microvessels density assessment in the tumor patients with early stages of NSCLC help to make conclusion that no statistical correlation between age, sex, body mass index of patients, locations, “T”, “N” criteria, stage of disease and microvessel density in the tumor presented. Also, no correlation between MD and histologyc type of tumor, necrosis in the tumor and infiltration of visceral pleura was founded.
- Microvessels density has important prognostic role, that was confirmed with univariate and multivariate analysis. We can use CD31/CD34 for prognosis in patients with early stages of NSCLC.
References
Cox G. A biological staging model for operable non-small cell lung cancer / G. Cox, J.L. Jones, A. Andi et al. // Thorax. – 2001. – № 56. – P. 561–566.
Donnem T. Inverse Prognostic Impact of Angiogenic Marker Expressionin Tumor Cells versus Stromal Cells in Non-Small Cell Lung Cancer / T. Donnem, S. Al-Saad, K. Al-Shibli et al. // Clin Cancer Res. – 2007. – № 13. – P. 6649–6657.
Fontanini G. Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study / G. Fontanini, M. Lucchi, S. Vignati et al. // Journal of the National Cancer Institute. – 1997. – Vol. 89. – № 12. – P. 881–886.
Giatromanolaki A. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer / A. Giatromanolaki, M.I. Koukourakis, D. Theodossiou et al. // Clin Cancer Res. – 1997. – № 3. – P. 2485–2492.
Guo J.F. Microvessel Density: Correlation with 18F-FDG Uptake and Prognostic Impact in Lung Adenocarcinomas / J.F. Guo, K. Higashi, Y. Ueda et al. // J Nucl Med. – 2006. – № 47. – P. 419–425.
Kakolyris S. Assessment of Vascular Maturation in Non-Small Cell Lung Cancer Using a Novel Basement Membrane Component, LH39: Correlation with p53 and Angiogenic Factor Expression / S. Kakolyris, A. Giatromanolaki, M. Koukourakis et al. // Cancer Res. – 1999. – № 59. – P. 5602–5607.
Matsuyama K. Tumor Angiogenesis as a Prognostic Marker
in Operable Non-Small Cell Lung Cancer / K. Matsuyama, Y. Chiba, M. Sasaki et al. // Ann Thorac Surg. – 1998. – № 65.
– P. 1405–1409.
Milas I. Association of VEGF, CD-34, E-cadherin and MMP-9
expression of the primary non-small cell lung cancer lesion with brain metastatic lesion / I. Milas, R. Komaki, T. Hachiya et al. // Proc Amer Assoc Cancer Res. – 2004. – Vol. 45. – Abstract #1919.
Mineo T.C. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer / T.C. Mineo, V. Ambrogi, A. Baldi et al // J Clin Pathol. – 2004. – №. 57. – P. 591–597.
Pusztaszeri M.P. Immunohistochemical Expression of Endothelial Markers CD31, CD34, von Willebrand Factor, and Fli-1 in Normal Human Tissues / M.P. Pusztaszeri, W. Seelentag and F.T. Bosman // J Histochem Cytochem. – 2006. – № 54. – P. 385.
Singhal S. Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review / S. Singhal, A. Vachani, D. Antin-Ozerkis et al. // Clin Cancer Res. – 2005. – № 11. – P. 3974–3986.
Tanaka F. Evaluation of Angiogenesis in Non-small Cell Lung Cancer: Comparison between Anti-CD34 Antibody and Anti-CD105 Antibody / F. Tanaka, Y. Otake, K. Yanagihara et al // Clin Cancer Res. – 2001. – № 7. – P. 3410–3415.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
